22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- PLA slams British hype over patrol vessel's Taiwan Strait transit
- Xi meets New Zealand's PM
- Chinese researchers develop cocktail hydrogel for brain injury therapy
- China unveils initiative to safeguard personal information of minors
- Zhangjiajie scenic area closes temporarily due to heavy rainfall
- China's vice-premier calls for consolidation of poverty alleviation work
